Daniel Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Daniel Collins
Company & Industry OverviewsAnalyzing CARA, INSY, and GWPH’s Earnings Trends
GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.
Company & Industry OverviewsCARA, INSY, and GWPH: Analysts’ Recommendations in January
On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.
Company & Industry OverviewsMarijuana Stock iAnthus Capital Already Up ~23% in January
Today, on the OTC markets, iAnthus Capital Holdings stock (ITHUF) is trading ~3.63% above yesterday’s closing price of $4.84.
Company & Industry OverviewsCharlotte’s Web Holdings’ Stock Grew ~11% Last Week
On January 25, Charlotte’s Web Holdings’ (CWBHF) stock price closed at $14.41, ~4.87% higher than its closing price of $13.74 on January 24 and ~11% higher than its closing price of $6.21 on January 18.
Company & Industry OverviewsCannTrust Holdings’ Stock Grew ~11% Last Week
On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.
Company & Industry OverviewsInnovative Industrial Properties’ Stock Grew ~10% Last Week
On January 25, Innovative Industrial Properties (IIPR) stock price closed at $59.94, ~3.52% higher than its closing price of $57.90 on January 24 and ~10% higher compared than its closing price of $54.32 on January 18.
Company & Industry OverviewsWhy Auxly Cannabis Group Stock Grew ~6.75% on January 25
On January 25, on the OTC markets, Auxly Cannabis Group’s stock price closed at $0.72, which is ~6.75% higher than its close of $0.67 on January 24 and reflects ~8% growth YTD (year-to-date).
Company & Industry OverviewsFDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%
Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.
Company & Industry OverviewsWhich Cannabis Stocks Were in the Green on January 24?
On January 24, Cannabis Strategic Ventures stock closed at $1.69—an ~8.33% rise compared to its closing price of $203.66 on January 23.
Company & Industry OverviewsCara Therapeutics: Earnings Trends and Recent Developments
In the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively.
Company & Industry OverviewsCara Therapeutics: A Financial Overview in January
In the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million.
Company & Industry OverviewsCara Therapeutics Has Risen ~18% in January
Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31.
Earnings ReportJohnson & Johnson Releases Its 2018 Results: Revenue Up 6.7%
Today, Johnson & Johnson (JNJ) released its fourth-quarter and 2018 financial results.
Company & Industry OverviewsBC Supreme Court Approves iAnthus and MPX’s Deal
On January 18, iAnthus Capital Holdings stock closed at $4.7, ~5.18% higher than its close of $4.5 on January 17, 2019.
Company & Industry OverviewsCharlotte’s Web Holdings Stock Has Already Risen ~18% in January
Charlotte’s Web Holdings reached $13.04 on January 18, which represents an ~18% YTD increase.
Company & Industry OverviewsAptinyx Stock Plunged 70% after Clinical Trial Failure
Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.
Company & Industry OverviewsBoston Scientific and Edward Lifesciences Settle Patent Dispute
Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.
Company & Industry OverviewsHow Is Green Thumb Industries Financially Positioned in January?
Green Thumb Industries reported net revenue of $17.17 million in the third quarter of 2018. What do analysts expect for the fourth quarter?
Company & Industry OverviewsGTBIF Acquires Advanced Grow Labs and Enters Connecticut Market
In January, Green Thumb announced that it had entered into a definitive agreement to acquire Advanced Grow Labs for a value of $80.0 million.
Company & Industry OverviewsGreen Thumb Industries Has Already Risen ~50% in January
On January 11, Green Thumb Industries (GTBIF) stock closed at $12.05, up ~15% from its previous week’s closing price.
Company & Industry OverviewsHow INSYS Therapeutics’ Earnings Were Trending
In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively.
Company & Industry OverviewsHow Is INSYS Therapeutics Financially Positioned in January?
In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.
Company & Industry OverviewsCannabis Stock INSYS Therapeutics Has Risen 28% in January
On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.
Company & Industry OverviewsHere Are Some of GW Pharmaceuticals’ Key Growth Drivers
GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.
Company & Industry OverviewsHow GW Pharmaceuticals’ Earnings Are Trending
In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.
Company & Industry OverviewsA Look into GW Pharmaceuticals’ Revenue Trends
In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.
Company & Industry OverviewsGW Pharmaceuticals Has Already Soared 23% in January
GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.
Company & Industry OverviewsWhy Globus Medical Stock Rose 10% on January 9
On January 9, Globus Medical was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8.
Company & Industry OverviewsCannTrust Holdings: Analysts Are Mainly Positive in January
On January 8, CannTrust Holdings’ (CNTTF) stock price closed at $5.63, which is ~3.04% growth from its close of $5.47 on January 7.
Company & Industry OverviewsAuxly Cannabis: Business Strategies and Financial Projections
Analysts expect Auxly Cannabis to report a net income of -40.08 million Canadian dollars in fiscal 2018.
Company & Industry OverviewsAuxly Cannabis: Analyzing the Stock Performance
Auxly Cannabis’ stock price closed at $0.67 on January 7, which is ~52% growth from its 52-week low of $0.44 on December 24.
Company & Industry OverviewsWhy CRISPR Therapeutics Stock Rose ~13.05% Yesterday
On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.
Company & Industry OverviewsWhy Neurocrine Biosciences Stock Rose 9.6% Yesterday
On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.
Company & Industry OverviewsHow Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
Company & Industry OverviewsA Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
Company & Industry OverviewsSarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Company & Industry OverviewsSage Therapeutics: Results from the Phase 3 ROBIN Trial
On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. SAGE-217 met the clinical trial’s primary and secondary endpoints.
Company & Industry OverviewsWhy Portola Pharmaceuticals Rose 8.09% on January 4
On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,
Company & Industry OverviewsWhy Epizyme Stock Rose ~33% on January 4
Of the ten analysts tracking Epizyme in January, four of them recommend a “strong buy,” while another four analysts recommend a “buy.”
Company & Industry OverviewsWhat to Expect from BMY’s Celgene Acquisition
The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.
Company & Industry OverviewsBristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.
Company & Industry OverviewsLet’s Talk about Bristol-Myers Squibb’s 2019 EPS Guidance
Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.
Company & Industry OverviewsHow Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
Company & Industry OverviewsA Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Company & Industry OverviewsWhy Tandem Diabetes Care Stock Soared Over 1,480% in 2018
Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.
Company & Industry OverviewsSpectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.
Company & Industry OverviewsSpectrum Pharmaceuticals: Financial Overview in December
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.
Company & Industry OverviewsTeva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.
Company & Industry OverviewsA Financial Overview of Teva Pharmaceutical in December
In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.
Company & Industry OverviewsTeva Pharmaceutical Stock Rose More than ~8% on December 26
On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.
Company & Industry OverviewsPfizer’s Prevnar 13 and Other Developments
Pfizer’s (PFE) Prevnar (or Prevenar) 13 is used to prevent pneumococcal diseases.
Company & Industry OverviewsPfizer’s Vaccines: A Look at Their Market Performance
In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.
Company & Industry OverviewsXtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth
In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.
Company & Industry OverviewsHow Pfizer’s Sutent and Xalkori Have Performed
In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.
Company & Industry OverviewsThis Drug Is Expected to Be a Significant Driver for Pfizer
In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.
Company & Industry OverviewsPfizer and GlaxoSmithKline’s Joint Venture: What to Expect
The new joint venture between GlaxoSmithKline and Pfizer will enable GlaxoSmithKline to strengthen its consumer healthcare business.
Company & Industry OverviewsPfizer and GlaxoSmithKline’s Consumer Health Business
Pfizer’s (PFE) consumer health business generated revenues of $2.6 billion during the first nine months in 2018.
Company & Industry OverviewsPfizer and GlaxoSmithKline Form a Joint Venture
On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.
Company & Industry OverviewsWhy Allergan Stock Fell 7% Today
Allergan (AGN) is trading at $135.98, which is a ~7.47% decline from its close of $146.76 on December 18.
Company & Industry OverviewsPfizer’s Stock Performance and Earnings Trends
On December 17, Pfizer’s stock price closed at $43.11, which is an ~1.58% decline from its close of $43.80 on December 14.
Company & Industry OverviewsAnalyzing Pfizer’s Revenues in December
Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.
Company & Industry OverviewsWhy Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.
Company & Industry OverviewsWhy Neurocrine Biosciences Stock Is Plummeting Today
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.
Company & Industry OverviewsHow Did Medtronic’s Restorative Therapies Group Perform?
Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.
Company & Industry OverviewsHow Does Medtronic’s Restorative Therapies & Diabetes Group Look?
Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty and Pain therapies.
Company & Industry OverviewsHow Medtronic’s Minimally Invasive Therapies Group Has Performed
Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.
Company & Industry OverviewsA Look at Medtronic’s Cardiac & Vascular Group’s Revenue Streams
Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019.
Company & Industry OverviewsHow Medtronic’s Cardiac and Vascular Group Performed
Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.
Company & Industry OverviewsA Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.
Company & Industry OverviewsHow Wall Street Analysts View Medtronic in December
Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”
Company & Industry OverviewsWhy Portola Pharmaceuticals’ Stock Price Is Plummeting Today
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.
Company & Industry OverviewsBausch’s Ultra Multifocal Contact Lenses Get FDA Approval
On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.
Company & Industry OverviewsGlaxoSmithKline Agreed to Acquire Tesaro
On December 3, GlaxoSmithKline (GSK) entered into an agreement with Tesaro (TSRO). GlaxoSmithKline will acquire Tesaro for ~$5.1 billion.
Company & Industry OverviewsWhy Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Company & Industry OverviewsWhy Exelixis Stock Soared 46% in November
Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.
Company & Industry OverviewsIQVIA Stock Has Increased 36% in 2018
On November 29, IQVIA Holdings’ (IQV) stock price closed at $124.95, which is ~6% growth from its close of $117.73 on November 23.
Company & Industry OverviewsExpress Scripts Holding Stock Has Risen 36% in 2018
On November 29, Express Scripts Holding’s stock price closed at $101.22, which is ~5% growth from the close of $96.81 on November 23.
Company & Industry OverviewsUnited Health Group Stock Has Risen 28% in 2018
On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23.
Company & Industry OverviewsHow BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Company & Industry OverviewsWhy Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
Company & Industry OverviewsIllumina Stock Has Jumped 45% Year-to-Date
On November 26, Illumina (ILMN) stock closed at $316.79, a rise of ~2.03% from its previous close of $310.50 on November 23.
Company & Industry OverviewsWall Street Analysts Are Mostly Positive on Abiomed
On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23.
Company & Industry OverviewsA Closer Look at Dexcom Stock’s 117% Year-to-Date Growth
On November 23, Dexcom (DXCM) stock closed at $124.28, a rise of ~2.20% from its previous day’s close of $121.61.
Company & Industry OverviewsWhy Analysts Are Mostly Positive on Boston Scientific Stock
Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.
Company & Industry OverviewsIntuitive Surgical Stock Has Seen Growth of 34% Year-to-Date
Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.
Company & Industry OverviewsTandem Diabetes Care Stock Has Skyrocketed in 2018
On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.
Company & Industry OverviewsMirati Therapeutics Stock Has Delivered Solid Growth in 2018
On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.
Company & Industry OverviewsArrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.
Company & Industry OverviewsEndocyte Stock Has Seen a Solid Hike in 2018
Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018.
Company & Industry OverviewsUnited Therapeutics: Recent Developments and Analysts’ Ratings
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).
Company & Industry OverviewsWhy Has AstraZeneca’s Stock Price Increased in 2018?
On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.
Company & Industry OverviewsGlaxoSmithKline Stock Has Increased ~15% in 2018
On November 19, GlaxoSmithKline’s stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16.
Company & Industry OverviewsAnalyzing Eli Lilly’s Stock Price and Financial Performance
On November 16, Eli Lilly’s (LLY) stock price closed at $113.83, which represents ~1.45% growth from its close of $112.20 on November 15.
Company & Industry OverviewsMerck’s Stock Price Has Increased ~34% in 2018
On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.
Company & Industry OverviewsPfizer Stock Has Risen ~20% in 2018
Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.
Company & Industry OverviewsHow Bausch Health’s Diversified Products Segment Has Performed
Bausch Health’s (BHC) Diversified segment consists of neurology, generics, dentistry, and other drugs.
Company & Industry OverviewsHow Is Salix Pharmaceuticals Positioned in November?
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.
Company & Industry OverviewsHow Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
Company & Industry OverviewsuniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
Company & Industry OverviewsWhere Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand
Jazz Pharmaceuticals’ Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017.